Triple Therapy for Cystic Fibrosis Phe508del–Gating and –Residual Function Genotypes
Triple Therapy for Cystic Fibrosis Phe508del–Gating and –Residual Function Genotypes
About this item
Full title
Author / Creator
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
To the Editor:
Given that the minimal clinically important difference in the percentage of predicted forced expiratory volume in 1 second (FEV
1
) is considered to be 5 percentage points,
1
the between-group difference of 3.5 percentage points in the percentage of predicted FEV
1
with elexacaftor–tezacaftor–ivacaftor, as compar...
Alternative Titles
Full title
Triple Therapy for Cystic Fibrosis Phe508del–Gating and –Residual Function Genotypes
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2607578582
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2607578582
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMc2115966
